Han Kun Advises Transcenta Holding on its New JCT205 Drug Project
April, 2019 - Beijing, Mainland China
The Center for Drug Evaluation under the National Medical Products Administration has recently accepted the investigational new drug application for a new death receptor 5 agonist antibody (JCT205) jointly developed by Transcenta Holding and U.S.-based InhibRx. JCT205 is intended for use as a monotherapy for treating various tumors, such as digestive tract tumors and mesothelioma. Previously, JCT205 was also entered into a Phase I clinical study in the United States in December 2018.
Transcenta Holding is a world-class biotherapeutics company with fully-integrated capabilities in research, development and manufacturing of biologics, established through the merger of HJB (Hangzhou) Co., Ltd. (HJB) and MabSpace Biosciences Co., Ltd., (MabSpace).
Han Kun provided full legal support to Transcenta Holding as PRC counsel during its collaboration with InhibRx in the JCT205 project.
